4th October 2016. Oxfordshire, UK. Sense Biodetection Limited (Sense) has today announced the formation of an advisory panel comprising a number of industry leading figures who will support the company through its next important stages of growth.
The founder members of the panel are:
Dr John Pritchard: Former VP R&D at Genzyme Diagnostics and Commercial Director of Diagnostics and Life Sciences at Cambridge Consultants. Currently Entrepreneur-in Residence at Cambridge Enterprise Seed Fund, University of Cambridge.
Prof John Wain: Formerly of Imperial College, The Sanger Institute, founder of antimicrobial drug discovery companies Discuva and Bectevo. Currently Professor of Medical Microbiology at the University of East Anglia.
Dr Catherine Beech, OBE: Serial Biotech entrepreneur, formerly CEO of Oval Medical Technologies and current CEO of Exonate.
Prof Michael Moore: Formerly CEO of Piramed. Current chairman of Mission Therapeutics, non-executive director of Trillium and Psioxus.
Sense CEO, Dr Harry Lamble, commented: “We are privileged to receive the support of such an impressive group of advisors whose complementary expertise from diverse backgrounds will bring powerful strategic guidance to the development of Sense. The advice of such high calibre individuals will help ensure the company’s success during the current exciting phase of business growth”. Sense anticipates making further appointments to the panel in the coming months.
About Sense: Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred tests in the fields of infections and oncology. The company is developing simple handheld tests to bring molecular diagnostics to the point-of-care, rather than complex instruments operated by trained users in central labs, which are the mainstay of the molecular diagnostics field. The company is backed by venture capital group Mercia (www.merciatechnologies.com) as well as a consortium of private business angels